Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting
Bionomics (BNOX) has announced its upcoming presentation at the 63rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, AZ, from December 8-11, 2024. The company will present results from their Phase 2 ATTUNE trial of BNC210 in post-traumatic stress disorder during the inaugural 'Promising Targets' session.
The presentation, titled 'Randomized, Double-Blind Study of BNC210, a Negative Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor, in Posttraumatic Stress Disorder (PTSD): The Attune Trial,' will be delivered by Murray Stein, M.D., M.P.H. on December 8, 2024, at 3:00 pm. The presentation slides will be made available on the company's website under the Publications webpage after the meeting.
Bionomics (BNOX) ha annunciato la sua prossima presentazione al 63° Congresso annuale del American College of Neuropsychopharmacology (ACNP) a Phoenix, AZ, dal 8 all'11 dicembre 2024. L'azienda presenterà i risultati del loro trial ATTUNE di Fase 2 di BNC210 nel disturbo da stress post-traumatico durante la sessione inaugurale 'Obiettivi Promettenti'.
La presentazione, intitolata 'Studio Randomizzato, in Doppio Cieco di BNC210, un Modulatore Allostrico Negativo del Recettore α7 dell'Acetilcolina Nicotinica, nel Disturbo da Stress Post-Traumatico (PTSD): Il Trial Attune,' sarà tenuta da Murray Stein, M.D., M.P.H. l'8 dicembre 2024, alle 15:00. Le diapositive della presentazione saranno rese disponibili sul sito web dell'azienda nella pagina Pubblicazioni dopo il congresso.
Bionomics (BNOX) ha anunciado su próxima presentación en el 63º Congreso Anual de la American College of Neuropsychopharmacology (ACNP) en Phoenix, AZ, del 8 al 11 de diciembre de 2024. La empresa presentará los resultados de su ensayo ATTUNE de Fase 2 de BNC210 en trastorno por estrés postraumático durante la sesión inaugural 'Objetivos Prometedores'.
La presentación, titulada 'Estudio Aleatorizado, Doble Ciego de BNC210, un Modulador Alostérico Negativo del Receptor α7 de Acetilcolina Nicotínica, en Trastorno por Estrés Postraumático (PTSD): El Ensayo Attune,' será presentada por Murray Stein, M.D., M.P.H. el 8 de diciembre de 2024, a las 3:00 p.m. Las diapositivas de la presentación estarán disponibles en el sitio web de la empresa en la página de Publicaciones después de la reunión.
비오노믹스 (BNOX)는 미국신경정신약리학회(ACNP) 제63회 연례 회의에서 2024년 12월 8일부터 11일까지 애리조나주 피닉스에서 발표할 예정이라고 발표했습니다. 이 회사는 BNC210에 대한 2상 ATTUNE 시험의 결과를 외상 후 스트레스 장애에 대해 첫 번째 ‘유망한 목표’ 세션에서 발표할 것입니다.
‘BNC210, α7 니코틴 아세틸콜린 수용체의 네거티브 알로스테릭 조절제에 의한 외상 후 스트레스 장애(PTSD): ATTUNE 시험의 무작위 이중 맹검 연구’라는 제목의 발표는 머레이 스틴 박사(M.D., M.P.H.)에 의해 2024년 12월 8일 오후 3시에 진행됩니다. 발표 슬라이드는 회의 후 회사 웹사이트의 출판물 웹페이지에 게시될 예정입니다.
Bionomics (BNOX) a annoncé sa prochaine présentation lors de la 63ème Réunion Annuelle de l'American College of Neuropsychopharmacology (ACNP) à Phoenix, AZ, du 8 au 11 décembre 2024. L'entreprise présentera les résultats de leur essai ATTUNE de Phase 2 sur BNC210 dans le cadre du trouble de stress post-traumatique lors de la séance inaugurale intitulée 'Cibles Prometteuses'.
La présentation, intitulée 'Étude Randomisée, en Double Aveugle de BNC210, un Modulateur Allostérique Négatif du Récepteur α7 de l'Acétylcholine Nicotinique, dans le Trouble de Stress Post-Traumatique (PTSD) : L'Essai Attune,' sera présentée par Murray Stein, M.D., M.P.H. le 8 décembre 2024 à 15h00. Les diapositives de la présentation seront mises à disposition sur le site web de l'entreprise dans la page Publications après la réunion.
Bionomics (BNOX) hat seine bevorstehende Präsentation auf dem 63. jährlichen Treffen des American College of Neuropsychopharmacology (ACNP) in Phoenix, AZ, vom 8. bis 11. Dezember 2024 angekündigt. Das Unternehmen wird Ergebnisse aus ihrer Phase 2 ATTUNE-Studie zu BNC210 bei posttraumatischer Belastungsstörung während der Eröffnungssitzung 'V vielversprechende Ziele' präsentieren.
Die Präsentation mit dem Titel 'Randomisierte, Doppelblinde Studie zu BNC210, einem negativen allosterischen Modulator des α7 Nikotinacetylcholinrezeptors, bei posttraumatischer Belastungsstörung (PTSD): Die ATTUNE-Studie,' wird am 8. Dezember 2024 um 15:00 Uhr von Murray Stein, M.D., M.P.H. gehalten. Die Präsentationsfolien werden nach der Sitzung auf der Webseite des Unternehmens unter dem Bereich Publikationen verfügbar sein.
- None.
- None.
ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be giving oral presentation on the results of the Phase 2 ATTUNE trial of BNC210 in post-traumatic stress disorder in the inaugural “Promising Targets” session at the 63ʳᵈ Annual Meeting of the American College of Neuropsychopharmacology (ACNP) being held December 8-11, 2024 in Phoenix, AZ.
Oral Presentation Details:
Title: Randomized, Double-Blind Study of BNC210, a Negative Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor, in Posttraumatic Stress Disorder (PTSD): The Attune Trial
Presenter: Murray Stein, M.D., M.P.H.
Session: Promising Targets
Date and Time: December 8, 2024 at 3:00 pm
Following the meeting, the slides from the oral presentation will be available under the Publications webpage of the Company’s website.
FOR FURTHER INFORMATION PLEASE CONTACT:
| General Rajeev Chandra Company Secretary CoSec@bionomics.com.au | Investor Relations Kevin Gardner kgardner@lifesciadvisors.com | Investor Relations Chris Calabrese ccalabrese@lifesciadvisors.com |
About Bionomics Limited
Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other CNS conditions. Bionomics’ pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need. www.bionomics.com.au
Forward-Looking Statements
Bionomics cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the closing of each tranche of the Company’s private placement financing, the achievement of certain milestones for the various tranches, the timely funding to the Company by each investor in the private placement, the timing, size and expectation of the closing of the private placement; and expectations regarding market conditions, the satisfaction of customary closing conditions related to the private placement and the anticipated use of proceeds therefrom; and the Company’s expectation that its current cash, cash equivalents, and marketable securities will fund our operations into the third quarter of 2025. The inclusion of forward-looking statements should not be regarded as a representation by Bionomics that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the Securities and Exchange Commission (SEC), including, but not limited to, the Company’s Annual Report on Form 20-F filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Bionomics undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks, uncertainties and other factors is included in Bionomics’ filings with the SEC, copies of which are available from the SEC’s website (www.sec.gov) and on Bionomics’ website (www.bionomics.com.au) under the heading “Investor Center.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Bionomics expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.
FAQ
When will Bionomics (BNOX) present their ATTUNE trial results at ACNP 2024?
What is the focus of Bionomics' (BNOX) Phase 2 ATTUNE trial presentation?
Where can investors find Bionomics' (BNOX) ACNP presentation slides?
Who will present Bionomics' (BNOX) ATTUNE trial results at ACNP 2024?
